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these major problems. Transfection of proximal pul-
monary artery segments (PPAS) and subsequent gene
expression offer certain advantages over more wide-
I schemia-reperfusion injury and rejection remainmajor obstacles to successful transplantation.1 Gene
transfer to the lung graft has the potential to reduce
Objective: Proximal pulmonary artery segment transfection may provide
beneficial downstream effects on the whole-lung graft. In this study,
transforming growth factor-b 1 was transfected to proximal pulmonary
artery segments, and the efficacy of transforming growth factor-b 1 trans-
fection was examined in ischemia-reperfusion injury and acute rejection
models of rat lung transplantation. Methods: In the ischemia-reperfusion
injury model, orthotopic left lung transplantation was performed in F344
rats. In group I, the PPAS was isolated and injected with saline solution.
In 2 other groups, lipid67:DOPE:sense (group II) or antisense trans-
forming growth factor-b 1pDNA construct (group III) was injected in-
stead of saline solution. After cold preservation at 4°C for 18 hours, lung
grafts were implanted. Graft function was assessed 24 hours later. In the
acute rejection model, donor lung grafts were harvested. Proximal pul-
monary artery segments were injected with saline solution (group I) or
sense (group II) or antisense lipid gene construct (group III) and then
implanted. Graft function was assessed on postoperative day 5. Results: In
the ischemia-reperfusion injury study, there were no significant differ-
ences in oxygenation, wet-to-dry weight ratios, graft myeloperoxidase
activity, or transforming growth factor-b 1 levels in platelet-poor serum or
proximal pulmonary artery segment homogenates. In the acute rejection
study, oxygenation was significantly improved in group II receiving
transforming growth factor-b 1 (group II vs I and III, 136.0 ± 32.5 vs 54.0
± 9.6 mm Hg and 53.8 ± 14.8 mm Hg; P = .016 and .016). There were no
significant pathologic differences. Transforming growth factor-b 1 con-
centrations from proximal pulmonary artery segment homogenates in
group II were significantly higher compared with controls. Conclusions:
Ex vivo transfection of transforming growth factor-b 1 to proximal pul-
monary artery segments did not affect reperfusion injury of lung iso-
grafts. In acute rejection, however, ex vivo transfection of transforming
growth factor-b 1 to proximal pulmonary artery segments improved allo-
graft function. This suggests that transfection to proximal pulmonary
artery segments exerts beneficial downstream effects on the whole-lung
allograft. (J Thorac Cardiovasc Surg 1999; 117:705-13)
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spread gene delivery strategies. First, it is possible to
confine the cationic lipid:plasmid DNA complexes to
the isolated arterial segments and not expose other
organs to a gene product unnecessarily. In addition, in
cases of transfection with a therapeutic transgene,
down-stream effects of the secreted protein may be
beneficial to the whole graft. Finally, compared with
whole-lung transfection, the amount of transfection
complexes needed is definitely reduced. Transgene
expression efficiency might be maximized by the use of
a high vector to endothelial cell ratio, which is difficult
to use in whole-lung transfection because of toxicity
and ideal storage times.
Transforming growth factor–b 1 (TGF-b 1) is a ubiqui-
tous molecule that exerts immunosuppressive effects
on various target cells.2 Prolongation of graft survival
was demonstrated in rat islet xenografts.3 Transgenic
TGF-b 1 prolonged cardiac allograft survival in mice.4
TGF- b 1 also affects ischemic protection.5 TGF- b 1
reduced the myocardial infarct size in rats and the
amount of superoxide anions and maintained endothe-
lial-dependent coronary relaxation.6 Similarly, exoge-
nous TGF-b 1 exerted myocardial protection in felines
by inhibiting circulating neutrophils from adhering to
the endothelium.7
We hypothesized that TGF-b 1 gene transfection
might have a beneficial downstream effect and limit
ischemia-reperfusion injury and acute rejection of rat
lung grafts.
Materials and methods
Cationic lipid:pDNA complexes. The plasmid pMP6A
sense and antisense TGF-b 1 were provided by Dr Jonathan
Bromberg (University of Michigan, Ann Arbor, Mich) and
amplified by Genzyme Corporation (Genzyme Corporation,
Framingham, Mass). The pMP6A sense TGF-b 1 encodes for
the mouse TGF-b 1 driven by the cytomegalovirus promoter.
Lipid 67 (GL-67; Genzyme Corporation) was provided by
Genzyme Corporation and used in a 1:2 molar ratio with the
neutral co-lipid, L-dioleoyl phosphatidyl-ethanolamine
(DOPE). Before use, dried lipid films were hydrated with
sterile water, treated in a vortex, placed on ice for 10 minutes,
and then placed in a vortex again. Equal volumes of
GL67:DOPE and plasmid DNA (sense or antisense TGF-b 1)
were mixed and incubated at room temperature for 30 min-
utes. Final concentrations were 1 mmol/L cationic lipid and 4
mmol/L plasmid DNA.
Animals. Inbred male F344 rats (Harlan Sprague-Dawley,
Inc, Indianapolis, Ind) were used in the ischemia-reperfusion
injury study and Brown Norway and F344 rats (Harlan
Sprague-Dawley, Inc) in the acute rejection study. All animals
weighed between 250 and 290 g. All animal procedures were
approved by the Animal Studies Committee at Washington
University. Animals received humane care in compliance
with “Principles of Laboratory Animal Care” formulated by
the National Society for Medical Research and the “Guide for
the Care and Use of Laboratory Animals” prepared by the
National Academy of Sciences and published by the National
Institutes of Health (NIH publication 85-23, revised 1985).
Ex vivo gene transfer to pulmonary artery segments. Ex
vivo transfection of pulmonary artery segments was per-
formed as previously described.8 After mechanical ventila-
tion and systemic heparinization, donor rat lungs were
flushed through the main pulmonary artery with 20 mL of
cold (4oC) low-potassium dextran–1% glucose solution.
Heart-lung blocks were extracted, and the left pulmonary
artery was isolated from the hilum to the pulmonary trunk.
Saline solution or lipid:gene constructs (0.03 mL) were
injected into the isolated left pulmonary artery segments with
a 24-gauge polyethylene catheter. Lung grafts were then
stored in low-potassium dextran–1% glucose solution at 4oC
for 1 hour, then the clamps isolating the PPAS were removed
from the pulmonary artery, and the lung grafts were returned
to the storage solution.
In the ischemia-reperfusion injury study, donor left-lung
grafts were implanted after 18 hours of cold preservation at
4oC. In the acute rejection study, lung grafts were implanted 1
hour after administration of the lipid:gene construct. Ortho-
topic left lung transplantation was performed by means of a
modification of the previously described “cuff technique.”9
Experimental design and groups
Ischemia-reperfusion injury study. Animals were divided
into 3 groups: saline solution control (group I; n = 6), sense
(group II; n = 6), and antisense (group III; n = 6) TGF-b 1
transfection groups. All animals were reanesthetized 24 hours
after reperfusion. The isolated function of the left lung iso-
graft was assessed by arterial blood gas analysis during
mechanical ventilation with 100% oxygen (tidal volume, 1.5
mL; respiratory rate, 100/min; positive end-expiratory pres-
sure, 1.0 cm H2O). Blood samples were obtained from the
ascending aorta for arterial blood gas analysis and quantita-
tion of TGF-b 1 in platelet-poor serum with an enzyme-linked
immunosorbent assay (ELISA).10 After the animals were
killed, the lung graft was flushed with cold saline solution
and removed from the thoracic cavity. This was then cut into
3 equal pieces perpendicular to the longitudinal axis. The
middle piece was frozen immediately in liquid nitrogen for
myeloperoxidase assay. The lower piece was weighed for
immediate determination of wet-to-dry weight ratio (W/D
ratio) and again after drying at 80oC for 48 hours. The
remaining upper piece was discarded. PPAS was put into 0.4
mL of cold acid-ethanol solution (93% ethanol, 2% concen-
trated hydrochloric acid [0.24 mol/L], 85 m g/mL phenyl-
methylsulfonyl fluoride, 5 m g/mL pepstatin A) and immedi-
ately homogenized for 1 to 2 minutes on ice with a tissue
tearer (Model 985-370 type II; Biospec Products Inc, Racine,
Wis).10
Acute rejection study. Three groups were created in the
same manner as in the ischemia-reperfusion injury study:
saline solution control (group I; n = 6), sense (group II; n =
6), and antisense (group III; n = 6) TGF-b 1 transfection
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groups. Before the animals were killed on postoperative day
5, blood samples were obtained for arterial blood gas analy-
sis and quantitation of TGF-b 1 in platelet-poor serum. The
lung graft was flushed with cold saline solution and fixed
with 10% neutral buffered formalin. Histopathologic speci-
mens of lung graft were stained with hematoxylin and eosin.
The lung grafts were examined by a blinded pathologist
(J.M.R.) experienced in the grading of rat lung acute rejec-
tion. The grafts were graded separately for acute vascular
rejection and airway inflammation with the revised working
formulation as described elsewhere.11 PPAS were placed into
0.4 mL of cold acid-ethanol solution and immediately
homogenized for 1 to 2 minutes on ice with a tissue tearer.
Myeloperoxidase assay. Quantitative myeloperoxidase
activity was determined as described previously.12 Optical
density (OD) was measured at 460 nm with a spectropho-
tometer (model PMQ II; Carl Zeiss, Oberkochen/Wuett,
Germany). The color development between these time points
had previously been determined to be linear for rat lung tis-
sue. One unit of enzyme activity was defined as the amount
of 1.0 OD units per minute per milligram of tissue protein at
room temperature.
ELISA for TGF-b 1. Blood samples (3 mL) were collected
into ethylenediaminetetraacetic acid-containing tubes with
phenylmethylsulfonyl fluoride (85 m g/mL) and pepstatin A (5
m g/mL).10 Serum was obtained by centrifugation at 3500g for
15 minutes and clarified by centrifugation at 10000g for 10
minutes. Then platelet-poor serum was stored at –80oC until
ELISA assessment. The PPAS homogenate was stored at 4oC.
After overnight extraction, the extract was clarified by cen-
trifugation at 10000g for 10 minutes and stored at –80oC. The
ELISA kit that is cross-active between human, mouse, and rat
was provided by Genzyme Corporation and used for quanti-
tation of TGF-b 1 levels. OD was measured at 450 nm with a
microplate reader (MR 600; Dynatech Laboratories Inc,
Alexandria, Va).
Statistical analysis. All values are presented as the mean ±
standard error of the mean. In the pathologic rejection score,
Kruskal-Wallis rank test was used to compare groups. In the
other assessments, 1-way analysis of variance with pairwise




Arterial blood gas analysis. Graft function was ana-
lyzed with the mean PaO2. The PaO2 in group II was
115.8 ± 30.0. There were no significant differences
between the 3 groups (PaO2 for groups I and III were
142.6 ± 62.2 and 139.9 ± 49.1, respectively; P = .704
and .733).
W/D weight ratio. As an assessment of graft injury,
W/D ratios were measured to evaluate graft edema for-
mation. The W/D ratio in group II was 7.23 ± 0.58.
There were no significant differences between the 3
groups (W/D ratio for groups I and III were 6.24 ± 0.67
and 6.62 ± 0.49, respectively; p = .251 and .469).
Myeloperoxidase assay. As another assessment of
graft injury, myeloperoxidase activity was measured to
evaluate the amount of neutrophils that attached to the
endothelial surface or migrated to interstitial spaces
across the endothelium and played an important role in
ischemia-reperfusion injury (Fig 1, A). Myeloperoxi-
dase activity in group II was 0.095 ± 0.01. There were
no significant differences between the 3 groups
(myeloperoxidase activity for groups I and III were
0.085 ± 0.013 and 0.109 ± 0.015, respectively; P = .589
and .475).
Acute rejection study
Arterial blood gas analysis. Allograft function was
assessed on the basis of mean arterial oxygen tension
values (Fig 1, B). The PaO2 in group II was significant-
ly higher than in control groups I and III (136.0 ± 32.5
versus 54.0 ± 9.6 mm Hg and 53.8 ± 14.8 mm Hg, for
groups II, I, and III, respectively; P = .016 and .016).
Histologic findings. The acute rejection scores are
shown in Fig 1, B. Grafts were graded separately for
acute vascular rejection and airway inflammation. The
cases that were difficult to classify were scored
between 2 grades. Most grafts were classified 2 (mild
acute rejection/airway inflammation) or 3 (moderate
acute rejection/airway inflammation). Acute vascular
rejection scores for groups II, I, and III were 2.42 ±
0.38, 2.67 ± 0.61, and 3.08 ± 0.30, respectively; P =
.476 and .070. Airway inflammation scores for groups
II, I, and III were 2.17 ± 0.21, 2.58 ± 0.30, and 2.67 ±
0.21, respectively; P = .300 and .211. There were no
significant differences between the groups.
ELISA for TGF-b 1. The quantitation of TGF-b 1 in
platelet-poor serum and PPAS homogenate is shown in
Fig 2. TGF-b 1 in platelet-poor serum in group II were
0.075 ± 0.029 ng/mL in the ischemia-reperfusion
injury study and 0.183 ± 0.056 ng/mL in the acute
rejection study. There were no significant differences in
platelet-poor serum between the groups in either the
ischemia-reperfusion injury study (TGF-b 1 in platelet-
poor serum for groups I and III were 0.066 ± 0.032
ng/mL and 0.085 ± 0.026 ng/mL, respectively; P = .826
and .807) or the acute rejection study (TGF-b 1 in
platelet-poor serum for groups I and III were 0.137 ±
0.057 ng/mL and 0.085 ± 0.004 ng/mL, respectively; P
= .494 and .154; Fig 2, A). In the ischemia-reperfusion
injury study, TGF-b 1 levels from group II PPAS
homogenates were significantly higher than group III
(1.00 ± 0.18 vs 0.42 ± 0.08 ng/pulmonary artery,
respectively; P = .005; Fig 2, B). In the acute rejection
study, TGF-b 1 levels from group II PPAS homogenates
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were significantly higher than controls (group II vs I
and III, 1.36 ± 0.23 ng/pulmonary artery vs 0.47 ± 0.05
and 0.40 ± 0.02 ng/pulmonary artery, respectively; P =
.003 and .001; Fig 2, B).
Ex vivo PPAS transfection and ex vivo whole–left
lung transfection. The comparison oxygenation data
of the degree of gene transfection between ex vivo
PPAS transfection and ex vivo whole–left lung trans-
fection is shown in Fig 3. Ex vivo whole–left lung
transfection was performed with 0.5 mL of the same
lipid:gene construct and the same exposure and
ischemic times. In the acute rejection model, oxygena-
tion in whole-lung transfection was more improved
than in PPAS transfection (234.2 ± 61.3 mm Hg vs
136.0 ± 32.5 mm Hg, respectively). However the
improvement was not significant (P = .187, unpaired t
test comparison). In the reperfusion injury model, lung
function of PPAS transfection group was higher than in
the whole-lung transfection group, although the differ-
ence was again not significant (152.1 ± 35.7 mm Hg vs
64.6 ± 13.5 mm Hg, respectively; P = .1314).
Discussion
Early lung graft dysfunction including ischemia-
reperfusion injury is not unusual during the first few
days after lung transplantation.13 Ischemia-reperfusion
injury is an acute lung injury with increased vascular
permeability. Pathophysiologic mechanisms of reper-
fusion injury are still unclear, but neutrophil migration
from the vasculature to the interstitial spaces plays a
major role in tissue injury.14,15
Acute lung allograft rejection occurs to a variable
degree in virtually all transplant recipients within the
first month after transplantation. Although acute rejec-
tion is infrequently fatal, it has been repeatedly identi-
fied as the principal risk factor for chronic rejection.13
Acute rejection is orchestrated primarily by helper T
lymphocytes that recognize donor major histocompati-





Fig 1. Acute rejection study. (A) The PaO2 in group II was significantly higher than groups I and III. (B) Rejection
scores. There were no significant differences between groups.
bility complex and that secrete cytokines that stimulate
the proliferation of cytotoxic T lymphocytes, which
effect graft injury.16
Numerous investigations into the function of TGF-b 1
have been performed. TGF-b 1 is 1 of a number of mul-
tifunctional molecules that exert global effects on cell
growth and differentiation, including embryonic devel-
opment, tumorigenesis, wound healing, and fibrosis. In
addition to these growth regulatory activities, TGF-b 1
has potent immunoregulatory effects. The immunosup-
pressive properties of TGF-b 1 include inhibition of thy-
mocyte proliferation,17-19 T- and B-cell prolifera-
tion,20-22 cytokine production,23 natural killer cell
activity,24 cytotoxic T-lymphocyte development,25-27
and lymphokine-activated killer cell activity.28 In the
field of reperfusion injury, TGF-b 1 inhibits leukocyte
adhesion to the endothelium and neutrophil migration
across the endothelium by diminishing E-selectin
expression29,30 and decreasing IL-8 synthesis.31 These
particular properties of TGF-b 1 were expected to be
sufficiently potent to ameliorate 2 major obstacles in
lung transplantation, namely ischemia-reperfusion
injury and rejection. We examined the efficacy of TGF-
b 1 transfection in rat ischemia-reperfusion injury and
acute rejection models.
In the reperfusion injury study, we expected endothe-
lial protection by TGF-b 1. However, no such protection
was noted after TGF-b 1 transfection. In the previous
studies on optimization of cationic lipid-mediated gene
transfer, reperfusion was an essential factor for ex vivo
transfection under the usual storage conditions.
Although transgene expression was apparent 3 hours
after reperfusion, maximal transgene expression was
obtained 24 hours after reperfusion (submitted for pub-
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Fig 2. Quantitation of TGF-b 1 with ELISA. (A) TGF-b 1 in platelet-poor serum. There were no significant differ-
ences in platelet-poor serum between groups in either the ischemia-reperfusion injury study or the acute rejection
study. (B) TGF-b 1 in homogenates of PPAS. TGF-b 1 levels in the PPAS homogenates from group II were signif-
icantly higher than in group III in the ischemia-reperfusion injury study. In the acute rejection study, TGF-b 1 lev-
els in PPAS homogenates from group II were significantly higher than in the other groups.
lication). Ischemia-reperfusion injury begins immedi-
ately after reperfusion and is dramatically amplified
during the first 60 minutes of reperfusion.32,33
Furthermore, a significant increase in myeloperoxidase
activity, 1 of the parameters of neutrophil migration,
has been observed 120 minutes after reperfusion in
occluded rabbit lungs.34 Ischemia-reperfusion injury
may have already occurred before the expression of
TGF-b 1 after TGF-b 1 transfection. TGF-b 1 transfection
did not result in a significant increase in TGF-b 1 levels
obtained from the sense TGF-b 1 transfection group
compared with the saline solution control group in
PPAS homogenates. The quantitation of TGF-b 1 in the
PPAS homogenate in the reperfusion injury model is
lower than in the acute rejection model. We speculate
that the viability of the PPAS endothelium was
decreased during 18 hours of cold preservation because
transgene expression was maximized during 24 to 72
hours after reperfusion in the previous study and the
integrity of the transfected PPAS endothelium was
maintained after 18 hours cold preservation and 24
hours after transplantation (submitted for publication).
Many factors including acute shear stress and cytokines
(IL-1b , TNF-a ) induce endothelial cell TGF-b 1 synthe-
sis. This may be also a possible reason for no differ-
ences in the quantity of TGF-b 1 between groups. A sig-
nificant increase in TGF-b 1 was not apparent in the
platelet-poor serum in either ischemia-reperfusion
injury or acute rejection studies. This may mean that
PPAS transfection has an effect only in the lung, name-
ly local immunosuppression. The half-life of the TGF-
b 1 molecule in vivo is very short. Most TGF-b 1 mole-
cules in serum are immediately combined with
a 2-macrogloblin, changed to a latent form, almost
completely trapped by the liver, and scavenged.35 This
is the reason that it is difficult to maintain high con-
centrations of TGF-b 1 in the serum. Also this is the rea-
son that local TGF-b 1 transfection is expected to be
more effective than systemic TGF-b 1 administration.
In the acute rejection study, TGF-b 1 transfection was
manifested by significant increases in TGF-b 1 levels in
PPAS homogenates. Graft function, as assessed by
arterial oxygenation, showed significant improvements
after sense TGF-b 1 transfection. This improvement
may support our hypothesis of beneficial downstream
effects of PPAS transfection. As mentioned earlier in
this article, the TGF-b 1 molecules are immediately
combined with a 2-macrogloblin and changed to a
latent form. However, latent TGF-b 1 is activated on the
surface of endothelial cells.36 The presence of huge
pulmonary microvascular endothelia distal to the PPAS
is an advantage for activation of latent TGF-b 1. In the
present study, the improvement in graft function was
not so great. Likewise, in the pathologic assessment,
differences between the groups were not significant.
There was no clear evidence of ischemic damage in the
allografts, although this would be difficult to ascertain
histologically in the presence of acute rejection.
The absence of pathologic improvements in the grad-
ing of acute rejection is likely multifactorial. First, it is
difficult to accurately grade acute pulmonary rejection
in the rat. The situation is not akin to the clinical con-
dition, where acute rejection may be mild. Second,
many of the grafts had acute rejection scores between 2
and 3, making it harder to observe a truly statistical
benefit in such a narrow margin. Third, it was difficult
to ascertain the exact number of transfected cells.
Studies using in situ hybridization and immunohisto-
chemical analysis are ongoing to determine the per-
centage of transfected cells. Thus potentially, a smaller
number of cells was transfected than predicted, result-
ing in decreased effectiveness of gene expression.
The duration of the immunosuppressive effects of
TGF-b 1 transfection is not absolutely clear. Acute
rejection is a multifactorial process, with several over-
lapping and redundant pathways that, without treat-
ment, lead to graft failure. Although TGF-b 1 has many
diverse immunosuppressive actions, its ability to sup-
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Fig 3. Comparison between ex vivo PPAS transfection and ex
vivo whole–left lung transfection with PaO2. In acute rejec-
tion, whole-lung transfection resulted in improved oxygena-
tion compared with PPAS transfection, although this was not
statistically significant. In ischemia-reperfusion injury, the
PaO2 after PPAS transfection was higher after whole-lung
transfection although the difference was not significant.
press acute rejection for the long-term is limited
indeed. Further, even if TGF-b 1 gene therapy were able
to completely abolish acute rejection, its effect would
certainly be limited by the duration of transgene
expression, which is finite. Thus gene therapy for the
treatment of acute rejection likely represents a transient
immunosuppressive phenomenon, potentially on the
order of several days.
TGF-b 1 transfection may not be effective in the
reperfusion injury model. The effect of TGF-b 1 on
endothelial cell–derived vasoactive mediator release is
complex, and it is not evident whether vasodilator or
vasoconstrictors dominate.32 Likewise, although TGF-
b 1 has some anti-ischemic effects, its main effects are
immunosuppressive. The absence of a positive effect
on ischemia-reperfusion lung injury therefore may be
related to lack of a potent TGF-b 1 anti-ischemic effect.
Alternatively, the percentage of PPAS transfected with
TGF-b 1 may have been too low to effect a change on
ischemia-reperfusion injury. In addition, the effective-
ness of TGF-b 1 may have been quenched because it
was released upstream from the tissue that needs to be
affected, allowing the possibility that it may have been
scavenged in the bloodstream before being able to exert
an effect. Further, the 18-hour preservation time may
have resulted in severe reperfusion injury to the lung
that may not have been reversible or treatable. This
would then negate any potential beneficial effects from
TGF-b 1 therapy. Finally, lung models of reperfusion
injury are poor and may not be analogous to the human
situation.
In conclusion, ex vivo transfection of TGF-b 1 to
PPAS does not affect ischemia-reperfusion injury of
lung isografts after 18 hours of cold preservation.
However, in the setting of acute rejection, ex vivo trans-
fection of TGF-b 1 to PPAS improves graft oxygenation.
This suggests that PPAS transfection provides benefi-
cial downstream effects on the whole-lung graft.
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Discussion
Dr Robert C. Robbins (Stanford, Calif). You have devel-
oped an excellent concept for trying to improve the function
of autograft tissue. The use of ex vivo gene therapy has the
advantage that the allograft during the time of ischemia and
transport can be modified with certain genetic techniques that
have been reported today. It allows the modification of the
graft to occur with a more concentrated and effective method
than the use of systemic modification. It also avoids the treat-
ment of other organs. In selecting the target or the molecule
in genetic therapy, one must decide whether the target should
be blocked or increased because of the beneficial effects.
You have selected TGF-b because of its immunosuppres-
sive effects and its effects on ischemia and reperfusion, and I
think that is an excellent target.
You have selected a liposome as the vector for delivery of
genetic material. There are many different vectors that can be
used to deliver the DNA into the nucleus: either unmodified
DNA in a plasmid form, the use of liposomes as we have seen
reported here today, or the use of viral vectors. Each has its
own potential set of problems; however, the use of liposomes
seems to be an effective means for delivering DNA in this
study.
For any gene therapy study, there are 3 concepts that
remain important: the transfection efficiency, the efficacy of
the transfection, and the observed biologic effect.
The transfection efficiency simply states how effective one
is in getting the DNA construct localized into the nucleus.
The efficacy deals with measurement of mRNA protein lev-
els of the target to measure the effectiveness. And then final-
ly, obviously, the biologic effect is the end clinical result that
we see.
In the current study there were 3 groups; the control saline-
treated group, the sense-treated group, which tried to achieve
increased production of TGF-b , and the antisense treatment,
which I would have thought would have blocked TGF-b . I
think the results were particularly disappointing in that you
saw no effect on reperfusion injury and even though you saw
better oxygenation in the acute rejection model, pathologically
there were no differences.
Have you looked at the transfection efficiency?
Particularly, have you used epitope tag labeling of your vec-
tor and construct to see if you are getting the construct into
the nucleus?
Dr Yano. Actually we did not look at the efficacy or effi-
ciency of transfection in these studies.
Dr Robbins. It would be helpful in any future studies if
you do that because we could learn a lot from finding out
whether the problem with not seeing any difference in reper-
fusion injury was that you are not transfecting the cell.
Another option is to look at the transfection efficacy by look-
ing at mRNA levels. That also would give us some indication
as to whether you selected a poor target or whether your
method is not good. 
You selected 18 hours for your ischemia-reperfusion study,
and you pointed out in your paper that that might be a prob-
lem in trying to achieve good transfection efficiency and effi-
cacy. Have you performed any studies that look at the clini-
cally relevant 4- to 6-hour ischemic period. If you have, can
you comment on that?
Dr Yano. We have not looked at shorter ischemic times in
these studies.
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Dr Robbins. You used oxygenation from the aorta as your
end point for assessing graft function. There are other ways
to look more specifically at the transplanted lung function,
such as compliance studies, flow probes around the pul-
monary artery, and looking at the difference in pulmonary
artery and left atrial oxygenation. Have you any comment on
that or have you done any studies that would tell us more
specifically about the function of the lung?
Dr Yano. We have not investigated these other measures of
lung function.
Dr Robbins. Finally, have you combined this with other
immunosuppressants? We have tried blocking intercellular
adhesion molecules with antisense oligonucleotides and have
seen that alone it had no effect on acute rejection. Have you
tried to combine this strategy with other immunosuppres-
sants, and if you have done that whether you had seen any
difference in acute rejection?
Dr Yano. We have not done this.
Dr Mora. As a coauthor of the paper, I wanted to clarify
some of the points that Dr Robbins had raised. First, in terms
of the TGF- b 1 antisense cDNA that we used in the study,
this was simply the normal TGF- b 1 gene inserted in an
inverted manner in the original plasmid. This is different
from antisense oligonucleotides that are typically designed
to block a particular gene from forming functional protein
products. The antisense TGF- b 1 plasmid produced no func-
tional TGF-b 1 protein; therefore it served as a control in these
experiments. 
In terms of the efficiency of gene transfection, we have not
performed any epitope-tagging studies to determine how
much of the cDNA construct entered the nucleus after injec-
tion into the pulmonary artery. However, this is a great
suggestion.
The second question concerned the efficacy of gene trans-
fection. In a separate unrelated study, our laboratory has
recently demonstrated increased whole-lung TGF-b 1 mRNA
levels after intratracheal transfection of TGF-b 1 liposome–
cDNA complexes, using reverse-transcriptase polymerase
chain reaction. We have not performed that assay in this
study, however.
The third question asked about shorter lung graft ischemic
times of 4 to 6 hours, as opposed to the 18 hours used in these
experiments. We have not studied shorter ischemic times
extensively because our rodent model is not very sensitive in
terms of arterial oxygenation measurements at short graft
ischemic times. In the past, we had tried various ischemic
times and had decided to use 18 hours of ischemia as a model
of ischemia-reperfusion lung injury. I think that it would be
good, however, to reproduce the experiments using shorter
ischemic times to ascertain this.
With regard to the question whether other assays of lung
function were used, such as compliance testing of the grafted
lung, we have not attempted this because it would be quite
technically challenging in the rodent.
The last question asked whether systemic immunosuppres-
sion was attempted in any of these experiments. We have not
used standard immunosuppression in our experiments simply
because there are no data that this is beneficial in the setting
of transfection of active genes with liposomal complexes, as
in our study.
I hope this clarifies some of the issues raised by Dr
Robbins.
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